期刊
ANNALS OF ONCOLOGY
卷 20, 期 3, 页码 403-412出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdn603
关键词
cost effectiveness; drug approval; health-care access; health expenditures; innovative therapies; oncology
类别
To air challenging issues related to patient and market access to new anticancer agents, the Biotherapy Development Association-025EFan international group focused on developing targeted cancer therapies using biological agents-025EFconvened a meeting on 29 November 2007 in Brussels, Belgium. The meeting provided a forum for representatives of pharmaceutical companies and academia to interact with European regulatory and postregulatory agencies. The goal was to increase all parties' understanding of their counterparts' roles in the development, licensure, and appraisal of new agents for cancer treatment, events guided by an understanding that cancer patients should have rapid and equitable access to life-prolonging treatments. Among the outcomes of the meeting were a greater understanding of the barriers facing drug developers in an evolving postregulatory world, clarity about what regulatory and postregulatory bodies expect to see in dossiers of new anticancer agents as they contemplate licensure and reimbursement, and several sets of recommendations to optimize patients' access to innovative, safe, effective, and fairly priced cancer treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据